The Board of Directors of AMBEV S.A. has approved a capital increase resulting from the exercise of stock options granted under the company's Stock Option Plan. This plan was initially approved by shareholders on July 30, 2013, and the specific program for 2026 was approved on January 28, 2026. The capital increase amo...

Ambev S.A. is convening its Annual Ordinary and Extraordinary Shareholders' Meetings (AGOE) for April 30, 2026, to be held virtually. The agenda includes the approval of the 2025 financial statements, allocation of net profits, determination of board and fiscal council sizes, election of board members for a three-year ...

This filing provides a comprehensive manual for the Annual Ordinary and Extraordinary Shareholders' Meetings of Ambev S.A., scheduled for April 30, 2026. The meetings will be conducted exclusively online via the Ten Meetings digital platform. Key agenda items for the Ordinary Meeting include the approval of the 2025 fi...

This filing provides details on Ambev S.A.'s Ordinary and Extraordinary Shareholders' Meetings agenda, including the approval of the 2025 fiscal year financial statements, allocation of net profits, and election of board and fiscal council members. Key financial highlights for the fiscal year ended December 31, 2025, i...

This Form 6-K filing from Ambev S.A. details the procedures for shareholders to exercise their right to vote remotely for the Ordinary Shareholders' Meeting scheduled for April 30, 2026. Shareholders can submit their votes by completing a bulletin and sending it directly to the company via email ([email protected]) or th...

Ambev S.A. filed a Form 6-K containing a distance voting bulletin for an upcoming Extraordinary Shareholders' Meeting scheduled for April 30, 2026. The filing provides shareholders with instructions for remote voting procedures and outlines four key resolutions to be voted on. These include: 1) Amending Article 5 of th...

AstraZeneca PLC has announced positive results from its Phase III clinical program for efzimfotase alfa (ALXN1850), an investigational enzyme replacement therapy for hypophosphatasia (HPP). The MULBERRY trial in treatment-naïve pediatric patients demonstrated statistically significant improvements in bone health. The C...

Alpha Tau Medical Ltd. announced that an abstract detailing results from two clinical trials of its Alpha DaRT® therapy in pancreatic cancer patients has been accepted for an oral presentation at Digestive Disease Week (DDW) 2026. This marks the first time clinical results for Alpha DaRT in pancreatic cancer will be pr...

This filing is an amendment to Aptorum Group Limited's Form 6-K, disclosing information about a merger agreement with DiamiR Biosciences Corp. The merger involves Aptorum forming a subsidiary to merge with DiamiR, with DiamiR surviving as a subsidiary of Aptorum. The closing of the merger is subject to shareholder appr...

Aris Mining Corporation has filed a Form 6-K report detailing its 2026 Annual General Meeting of Shareholders, scheduled for May 7, 2026. The meeting will cover the presentation of the 2025 audited consolidated financial statements, the election of eight directors, the appointment of KPMG LLP as auditors, and resolutio...

BBVA announced the partial execution of a share capital reduction, approved by the Ordinary General Shareholders’ Meeting on March 20, 2026. The reduction involves canceling 74,963,302 treasury shares, each with a par value of 0.49 euros, totaling 36,732,017.98 euros. These shares were repurchased as part of a share bu...

Banco Santander-Chile has announced the placement of dematerialized bearer bonds in the local market. The bonds, Series AA-6 with ticker BSTDA61022, total 1,000,000 UF and mature on October 1, 2037. The average placement rate for these bonds was 2.80%. This placement was made using a line of credit registered with the ...

Belite Bio, Inc. announced on March 31, 2026, that its annual report on Form 20-F for the year ended December 31, 2025, has been filed with the Securities and Exchange Commission and is available on the company's website. Shareholders can request a hard copy free of charge. The press release is issued in accordance wit...

B.O.S. Better Online Solutions Ltd. reported strong financial results for the fourth quarter and full year 2025. For the full year 2025, revenues reached $50.6M, a 26.6% increase from 2024, with net income at $3.6M, up 57.0%. The fourth quarter also showed significant growth, with revenues of $12.6M (+21.5%) and net in...

B.O.S. Better Online Solutions Ltd. (BOS) announced on March 31, 2026, that it has filed its annual report for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission. The report includes audited consolidated financial statements. It is available on the company's website, and shareholders can...

Braskem S.A. has informed shareholders and the market about a transaction between related parties. Braskem, Petróleo Brasileiro S.A. – Petrobras, and Ultrapar Participações S.A. are jointly acting as debenture holders for Refinaria de Petróleo Riograndense S.A. (RPR), which they co-own. The transaction involves the 4th...

This Form 6-K filing details the resolutions from an Extraordinary General Meeting of Centrais Elétricas Brasileiras S.A. (Eletrobrás) held on April 1, 2026. The meeting addressed several key management proposals. Proposal 1 concerned the company's potential admission to the Novo Mercado special listing segment on B3, ...

This filing is a report from CENTRAIS ELÉTRICAS BRASILEIRAS S.A. - ELETROBRÁS for the month of March 2026. It details the results of a Special Meeting of Class "B1" Preferred Shareholders held on April 1, 2026. The primary resolution addressed was the approval of the conversion of all class B1 preferred shares into com...

This Form 6-K report details the resolutions from a Special Meeting of Class "A1" Preferred Shareholders of CENTRAIS ELÉTRICAS BRASILEIRAS S.A. - ELETROBRÁS, held on April 1, 2026. The primary resolution, approved with 62.484% of votes in favor, concerned the conversion of all class A1 preferred shares into common shar...

Centrais Elétricas Brasileiras S.A. - Eletrobrás has updated its Executive Compensation and Clawback Policy (PO-GN.01.005) effective October 23, 2025. This policy establishes principles and guidelines for executive compensation, aiming to attract and retain talent, foster a shared sense of purpose, and promote responsi...

BTQ Technologies Corp. reported its full-year 2025 corporate update, highlighting significant progress across its four core business lines: QCIM (quantum-secure elements), QPerfect (neutral atom platforms), QSSN (quantum-secure networks), and Bitcoin Quantum. The company emphasized its strategy to deploy quantum techno...

BTQ Technologies Corp. announced the appointment of Dr. Ro Cammarota to its U.S. team. Dr. Cammarota will focus on accelerating the development, commercialization, and strategic partnerships for QCIM, the company's post-quantum semiconductor platform. With over 20 years of experience in cryptography, privacy, and advan...

At a mandatory annual shareholders' meeting held on March 30, 2026, COMPAÑIA DE MINAS BUENAVENTURA S.A.A. approved seven key proposals. These included the appointment and removal of directors, the approval of the social management report and financial statements for the fiscal year 2025, and the distribution of profits...

BW LPG Limited has filed its 2025 Integrated Annual Report and its 2025 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (SEC). The Form 20-F includes the company's audited consolidated financial statements for the year ended December 31, 2025. The Integrated Annual Report, which incorporates...

This filing is a Report of Foreign Private Issuer on Form 6-K for the month of March 2026, filed by Bilibili Inc. The report includes Exhibit 99.1, a Next Day Disclosure Return dated March 31, 2026. This exhibit details changes in the issued shares of the company during March 2026. Specifically, it outlines the issuanc...